Disclaimer:

Disclaimer: The blog posts and comments on this blog and posts on social networks are not investment recommendation, are provided solely for informational purposes, and do not constitute an offer or solicitation to buy or sell any securities. The opinions expressed on the blog are Petar Posledovich's. Petar Posledovich does not guarantee the accuracy of the information presented on this blog and social networks. The information presented is "as is". The blog is stocks analysis and valuation, Bitcoin, Cryptocurrencies, Artificial Intelligence, AI, deep-learning focused. Independent, unbiased AI insights. Petar Vladimirov Posledovich is not liable for any investment losses incurred by reading and interpreting blog posts on this blog and posts on social networks. Conflicts of interest: I may possess some of the securities, currencies or their derivatives mentioned in the blog post and posts on social networks! The blog is property of Wolfteam Ltd. www.wolfteamedge.com Respectfully yours, Petar Posledovich

Saturday, July 20, 2024

Gilead Sciences Valuation

 


Gilead Sciences, the American biotechnology company is slightly undervalued, according to Wolfteam Ltd.'s projections and estimates.

With 27.12 billion USD revenue, declining at -0.60 % with net profit margin of 20.89 %, Gilead Sciences' intrinsic value is 108 billion USD compared to Gilead Sciences' current market capitalization of 90.40 billion USD.

Here is an excerpt from Gilead Sciences first quarter 2024 earnings report:

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS


Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion
Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion
Oncology Sales Increased 18% Year-Over-Year to $789 million
Closed CymaBay Acquisition Resulting in $3.9 billion Acquired IPR&D Charge ($3.14 Diluted EPS Impact

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)